FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558776811> ?p ?o ?g. }

• W2558776811 endingPage "146" @default.
• W2558776811 startingPage "146" @default.
• W2558776811 abstract "Abstract From July 1997 through June 2002, the German CLL Study Group conducted a prospective multicenter trial to assess the feasibility and efficacy of early SCT in patients with poor-risk chronic lymphocytic leukemia (CLL). The protocol comprised optional cytoreduction with CHOP, fludarabine, or FC; PBSC mobilization using the Dexa-BEAM regimen; and myeloablative therapy with TBI/CY followed by reinfusion of purged stem cells. Inclusion criteria were age <61 years, stage Binet B/C or poor-risk stage A as defined by short lymphocyte doubling time plus elevated STK, and one line of pretreatment or less. Endpoints were feasibility (as defined by the proportion of patients able to successfully undergo all study procedures); toxicity; efficacy; and quality of life (QOL) as defined by the Spitzer QOL Index. Results: As of July 2004, 128 of 179 eligible patients were evaluable. Median age was 51 (27–60) years. Binet stages were poor-risk A 15%; B 61%; C 24%. An unmutated VH rearrangement was present in 72%. Eighty-six percent of the patients were chemotherapy naive at study entry. Best documented response during the pretransplant phase was complete remission (CR) in 28% and partial remission (PR) in 64% of the patients, giving an overall response rate of 92%. Immunomagnetically purged grafts were obtained in 83% of the patients in whom mobilization was attempted, containing 4.6 (1.2–22.1) CD34+ cells per kg body weight. Altogether, 98 of 128 patients (77%) proceeded to SCT. Reasons for exclusion from SCT were disease progression, mobilization failure, toxicity during the mobilization phase, or patient’s refusal. At 3 months post SCT CR was reported in 78% and PR in 21%. With a follow-up time of 36 (3–77) months, median progression-free survival of all 128 patients intended to treat was 59 months (54 months for those with unmutated VH). 4-year overall survival of all 128 patients was 84% (95%CI 74–94). Grade 3/4 non-hematological toxicity was mainly due to infections, which occurred in 21% of the patients (18% pretransplant; 7% post transplant). Six complications were fatal (4 pretransplant, 2 post transplant), translating into a 5% probability of treatment-related death. A single case of treatment-related myelodysplasia / AML has been reported to date. One year after SCT, QOL index had the maximum score of 10 points in 48 of 57 evaluable patients (84%). In comparison to prestudy levels, QOL had increased in 35%, remained similar in 50%, and decreased in 15% of the patients. Conclusions: Early sequential high-dose therapy including SCT for poor-risk CLL is feasible and has promising efficacy. Whereas the transplant-related toxicity appears to be acceptable, future studies should aim at replacing Dexa-BEAM by a similarly effective but less toxic mobilization regimen." @default.
• W2558776811 created "2016-12-08" @default.
• W2558776811 creator A5002498295 @default.
• W2558776811 creator A5006107813 @default.
• W2558776811 creator A5007767373 @default.
• W2558776811 creator A5019866348 @default.
• W2558776811 creator A5030071814 @default.
• W2558776811 creator A5036867361 @default.
• W2558776811 creator A5055422099 @default.
• W2558776811 creator A5055498682 @default.
• W2558776811 creator A5061380659 @default.
• W2558776811 creator A5071552171 @default.
• W2558776811 creator A5075280681 @default.
• W2558776811 creator A5076077834 @default.
• W2558776811 creator A5079460815 @default.
• W2558776811 creator A5085146093 @default.
• W2558776811 creator A5089395073 @default.
• W2558776811 date "2004-11-16" @default.
• W2558776811 modified "2023-10-01" @default.
• W2558776811 title "Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3 Protocol)." @default.
• W2558776811 doi "https://doi.org/10.1182/blood.v104.11.146.146" @default.
• W2558776811 hasPublicationYear "2004" @default.
• W2558776811 type Work @default.
• W2558776811 sameAs 2558776811 @default.
• W2558776811 citedByCount "8" @default.
• W2558776811 countsByYear W25587768112016 @default.
• W2558776811 crossrefType "journal-article" @default.
• W2558776811 hasAuthorship W2558776811A5002498295 @default.
• W2558776811 hasAuthorship W2558776811A5006107813 @default.
• W2558776811 hasAuthorship W2558776811A5007767373 @default.
• W2558776811 hasAuthorship W2558776811A5019866348 @default.
• W2558776811 hasAuthorship W2558776811A5030071814 @default.
• W2558776811 hasAuthorship W2558776811A5036867361 @default.
• W2558776811 hasAuthorship W2558776811A5055422099 @default.
• W2558776811 hasAuthorship W2558776811A5055498682 @default.
• W2558776811 hasAuthorship W2558776811A5061380659 @default.
• W2558776811 hasAuthorship W2558776811A5071552171 @default.
• W2558776811 hasAuthorship W2558776811A5075280681 @default.
• W2558776811 hasAuthorship W2558776811A5076077834 @default.
• W2558776811 hasAuthorship W2558776811A5079460815 @default.
• W2558776811 hasAuthorship W2558776811A5085146093 @default.
• W2558776811 hasAuthorship W2558776811A5089395073 @default.
• W2558776811 hasConcept C126322002 @default.
• W2558776811 hasConcept C141071460 @default.
• W2558776811 hasConcept C168563851 @default.
• W2558776811 hasConcept C203092338 @default.
• W2558776811 hasConcept C2776694085 @default.
• W2558776811 hasConcept C2776755627 @default.
• W2558776811 hasConcept C2777938653 @default.
• W2558776811 hasConcept C2778461978 @default.
• W2558776811 hasConcept C2779015954 @default.
• W2558776811 hasConcept C2779263901 @default.
• W2558776811 hasConcept C2781413609 @default.
• W2558776811 hasConcept C2911091166 @default.
• W2558776811 hasConcept C71924100 @default.
• W2558776811 hasConcept C90924648 @default.
• W2558776811 hasConceptScore W2558776811C126322002 @default.
• W2558776811 hasConceptScore W2558776811C141071460 @default.
• W2558776811 hasConceptScore W2558776811C168563851 @default.
• W2558776811 hasConceptScore W2558776811C203092338 @default.
• W2558776811 hasConceptScore W2558776811C2776694085 @default.
• W2558776811 hasConceptScore W2558776811C2776755627 @default.
• W2558776811 hasConceptScore W2558776811C2777938653 @default.
• W2558776811 hasConceptScore W2558776811C2778461978 @default.
• W2558776811 hasConceptScore W2558776811C2779015954 @default.
• W2558776811 hasConceptScore W2558776811C2779263901 @default.
• W2558776811 hasConceptScore W2558776811C2781413609 @default.
• W2558776811 hasConceptScore W2558776811C2911091166 @default.
• W2558776811 hasConceptScore W2558776811C71924100 @default.
• W2558776811 hasConceptScore W2558776811C90924648 @default.
• W2558776811 hasIssue "11" @default.
• W2558776811 hasLocation W25587768111 @default.
• W2558776811 hasOpenAccess W2558776811 @default.
• W2558776811 hasPrimaryLocation W25587768111 @default.
• W2558776811 hasRelatedWork W1980281744 @default.
• W2558776811 hasRelatedWork W1982267297 @default.
• W2558776811 hasRelatedWork W2017979975 @default.
• W2558776811 hasRelatedWork W2047361930 @default.
• W2558776811 hasRelatedWork W2102297256 @default.
• W2558776811 hasRelatedWork W2131897387 @default.
• W2558776811 hasRelatedWork W2152025286 @default.
• W2558776811 hasRelatedWork W2392235713 @default.
• W2558776811 hasRelatedWork W2416027424 @default.
• W2558776811 hasRelatedWork W2588541019 @default.
• W2558776811 hasVolume "104" @default.
• W2558776811 isParatext "false" @default.
• W2558776811 isRetracted "false" @default.
• W2558776811 magId "2558776811" @default.
• W2558776811 workType "article" @default.